INHIBITOR Therapeutics, Inc.
4830 W. Kennedy Blvd.
36 articles with INHIBITOR Therapeutics, Inc.
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), today announced that the company has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate an IND-opening clinical study as a two-part, multi-center, randomized, double-blind, placebo-controlled, Phase 2b clinical trial t
Industry Veteran Brings 30 Years of Experience to Support INTI's Biopharmaceutical and Corporate Programs
HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), today announced plans to change its name to INHIBITOR Therapeutics as well as a change to the ticker symbol for common and preferred stock to "INTI" from "HPPI."
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
New method of use claims in lung cancer enhance HedgePath's intellectual property estate relating to SUBA-Itraconazole
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
Patent expected to issue coincident with HedgePath's 2019 efforts to clear IND for SUBA®-Itraconazole for the treatment of prostate cancer
HedgePath Pharmaceuticals, Inc. announced that HedgePath's Board of Directors has elected W. Mark Watson, CPA as Chairman of the Board, effective April 15, 2019.
Secured the potential for up to $5 million in new funding ($1.5 million of which has been funded to date) and further secured a 9% royalty on future U.S. sales of SUBA®-Itraconazole for basal cell carcinoma nevus syndrome (BCCNS) through revised agreement with majority shareholder and licensor Mayne Pharma Ventures Pty Ltd. (Mayne Pharma) Secured exclusive option to license next-generation itraconazole analogues from University of Connecticut (UCONN) for potential pipeline expansion, a
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) announced today that it has entered into a revised Supply and License Agreement (SLA) with its majority stockholder Mayne Pharma Ventures Pty Ltd (Mayne Pharma), an affiliate of Mayne Pharma Group Limited (ASX: MYX).
BIOBUSINESS: Spotlight on Innovation Monday, October 15, 2018 at the Westin Fort Lauderdale, Florida.
Key components of SUBA BCCNS NDA agreed to in FDA meeting minutes
HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request
FDA has confirmed HPPI's clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission
HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has signed an exclusive option agreement with the University of Connecticut (UConn) related to patents and patent applications covering certain chemical analogues of the Food and Drug Administration (FDA) approved anti-fungal drug itraconazole.
Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program
HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
HPPI preparing patient dossiers for a July face-to-face meeting with FDA with the goal of filing an NDA later in 2018 Additional promising clinical trial data also announced
HPPI's patent portfolio expands again with claims covering treatment of any non-cancerous proliferation disorders with itraconazole, the active ingredient in HPPI's current and anticipated future product candidates
HPPI's patent portfolio expands with claims covering treatment of both hematologic and non-hematologic cancers with itraconazole, the active ingredient in HPPI's current and anticipated future product candidates
HedgePath Pharma Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
This latest investment by Mayne Pharma will support HPPI's clinical and regulatory efforts during 2018 toward the anticipated filing of the SUBA-Itraconazole BCCNS NDA with FDA during 2018.
HedgePath Pharma announced today that it has completed enrollment in its previously announced open label, Phase 2b SCORING clinical trial, testing SUBA-Itraconazole in patients with BCCNS.
HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway To Potential Regulatory Submission
HedgePath Pharmaceuticals Announces Granting Of Type-C Meeting Request By FDA And Provides Positive Clinical Trial Update